Chemotherapy Treatment in Raipur

Chemotherapy uses cytotoxic drugs to kill or inhibit rapidly dividing cells. Unlike surgery and radiation, which act locally, chemotherapy acts systemically by travelling through the bloodstream to reach cancer cells throughout the body. This makes it particularly valuable for cancers that have spread or where microscopic spread cannot be determined from imaging alone.

Chemotherapy drugs interfere with DNA replication, disrupt cell division machinery or damage DNA directly, resulting in cancer cell death. Because rapidly dividing cells are the primary target, normal tissues with high cell turnover like gut lining, hair follicles and bone marrow are also affected, which accounts for the characteristic side effects.

Why Choose Ramkrishna CARE Hospitals for Chemotherapy Treatment in Raipur?

The delivery of chemotherapy safely and effectively requires more than a room with an infusion chair. It requires oncologists with subspeciality training, doctors with expertise in cytotoxic drug preparation, trained oncology nursing staff, and the clinical systems to monitor for and manage treatment-related complications. At Ramkrishna CARE Hospitals, Raipur, all of these are in place:

• Multidisciplinary tumour board: Every patient's chemotherapy regimen is determined after formal multidisciplinary review by medical oncologists, surgical oncologists, radiation oncologists, and radiologists. Treatment is not decided by a single doctor, but it reflects the collective clinical judgement of a specialist team.
• Dedicated oncology day care unit: A purpose-built chemotherapy administration facility staffed by oncology-trained nurses, with dedicated infusion chairs, pharmacy support and antiemetic and supportive medication protocols that make treatment as safe and comfortable as possible
• Full spectrum oncology support: Chemotherapy at Ramkrishna CARE Hospitals is not administered in isolation. It is coordinated with radiation therapy on the Elekta Versa HD, with PET-CT staging and response assessment on the uMI 550 Digital PET-CT and with surgical oncology creating integrated treatment plans rather than fragmented individual interventions.
• Modern supportive pharmacology: Antiemetic regimens substantially reduce chemotherapy-induced nausea; granulocyte colony-stimulating factors (G-CSF) reduce the risk and severity of neutropenia; erythropoiesis-stimulating agents and iron supplementation manage anaemia. These supportive measures are prescribed as part of the chemotherapy protocol.
• Biologic, targeted and immunotherapy agents: In addition to conventional cytotoxic chemotherapy, our oncology team administers targeted agents (tyrosine kinase inhibitors, HER2-directed antibodies, CDK4/6 inhibitors, and PARP inhibitors), monoclonal antibodies and checkpoint immunotherapy (anti-PD-1 and anti-PD-L1 agents) for approved indications across multiple cancer types.
• Response monitoring with PET-CT: Treatment response is assessed mid-course and at completion using our uMI 550 digital PET-CT system. The system's time-of-flight imaging and 2.76 mm crystal pixel resolution detect changes in metabolic activity before they are visible as changes in tumour size on conventional CT, allowing earlier identification of responding versus non-responding disease and timely treatment modification.

Types of Chemotherapy

Different chemotherapies are:

• Cytotoxic chemotherapy: This category includes drugs like platinum compounds (cisplatin, carboplatin, and oxaliplatin), anthracyclines (doxorubicin and epirubicin), taxanes (paclitaxel and docetaxel), alkylating agents (cyclophosphamide and ifosfamide), antimetabolites (5-fluorouracil, gemcitabine, and methotrexate) and vinca alkaloids (vincristine and vinorelbine). Each class acts through a different mechanism and is selected based on the cancer type and protocol.
• Targeted therapy: Drugs designed to interfere with specific molecular pathways driving cancer growth. These include tyrosine kinase inhibitors, HER2-directed VEGF inhibitors, CDK4/6 inhibitors for breast cancer and PARP inhibitors. These require prior biomarker testing to confirm target expression.
• Immunotherapy/checkpoint inhibitors: These include anti-PD-1 and anti-PD-L1 agents that restore immune system recognition of cancer cells. Used in lung cancer, melanoma, urothelial cancer, head & neck cancer and others, with eligibility determined by PD-L1 expression and microsatellite instability status
• Monoclonal antibody therapy: Agents such as rituximab (B-cell lymphomas), cetuximab (colorectal and head and neck cancers), and bevacizumab (colorectal and lung cancers) that target specific proteins on cancer cell surfaces or in the tumour microenvironment
• Hormone therapy: For hormone receptor-positive breast and prostate cancers, hormonal agents deprive cancer cells of the hormonal signals they depend on for growth.

Conditions Treated with Chemotherapy

Chemotherapy is used across the full spectrum of malignant disease. The following represent the most common cancer types treated at Ramkrishna. CARE Hospitals:

• Breast cancer: Adjuvant and neoadjuvant chemotherapy, HER2-directed therapy, CDK4/6 inhibitors, and hormone therapy
• Lung cancer: Platinum doublet chemotherapy, EGFR and ALK-targeted agents, checkpoint immunotherapy
• Gastrointestinal cancers: Colorectal, gastric, oesophageal, pancreatic and hepatocellular carcinoma, using combination chemotherapy
• Head and neck cancers: Concurrent cisplatin-based chemoradiation and cetuximab-based regimens
• Haematological malignancies: Intensive induction regimens for leukaemia; novel agent combinations for myeloma
• Gynaecological cancers: Carboplatin-paclitaxel for ovarian cancer; cisplatin concurrent with radiation for cervical cancer
• Urological cancers: Cisplatin-based combinations for bladder cancer; taxanes for prostate cancer
• Bone and soft tissue sarcomas: Combination chemotherapy regimens
• Paediatric cancers: Age-appropriate chemotherapy protocols for childhood leukaemia, lymphoma, and solid tumours.

How Chemotherapy Is Used to Treat Cancer

The chemotherapy choice depends on the stage of the cancer and its advancement:

• Curative intent: In cancers where chemotherapy can achieve complete remission, like haematological malignancies, many acute leukaemias, and testicular cancer
• Adjuvant chemotherapy: Given after surgery when the primary tumour has been resected but there is a risk of microscopic residual disease. Adjuvant chemotherapy reduces the probability of recurrence by treating occult micrometastases that surgery cannot address.
• Neoadjuvant chemotherapy: Given before surgery to shrink the tumour, making complete resection more feasible, or to treat micrometastatic disease early.
• Concurrent chemoradiation: Chemotherapy administered simultaneously with radiation therapy acts as a radiosensitiser, making tumour cells more vulnerable to radiation damage. Concurrent cisplatin with radiotherapy is the standard of care for locally advanced cervical cancer, head and neck cancers and selected lung and oesophageal cancers.
• Palliative chemotherapy: In metastatic or advanced cancer where a cure is not achievable, chemotherapy can reduce tumour burden, control symptoms, improve quality of life and extend survival. The goal shifts from cure to meaningful disease control with acceptable tolerability.

Risks and Possible Complications

Chemotherapy's action on rapidly dividing cells explains most of its side effects. The severity of side effects varies significantly depending on the agents used, the dose, the schedule and individual patient factors. The most commonly encountered include the following:

• Myelosuppression: Suppression of bone marrow production of blood cells, leading to anaemia (fatigue, breathlessness), neutropenia (increased infection risk) and thrombocytopenia (increased bleeding tendency). Blood count monitoring throughout treatment allows dose modifications and G-CSF prophylaxis when needed.
• Nausea & vomiting: Substantially reduced with modern antiemetic protocols. Most patients tolerate chemotherapy with manageable nausea when antiemetics are prescribed proactively.
• Hair loss (alopecia): Common with taxane- and anthracycline-based regimens, typically temporary. Hair regrowth begins within four to eight weeks of completing chemotherapy.
• Fatigue: One of the most commonly reported and often most limiting side effects caused by anaemia, sleep disruption, metabolic changes and the psychological burden of treatment
• Mucositis and mouth sores: Inflammation of the oral and gastrointestinal mucosa, causing mouth pain, difficulty swallowing and sometimes diarrhoea. Good oral hygiene and nutritional support reduce severity.
• Peripheral neuropathy: Numbness, tingling or pain in the hands and feet, particularly with taxane and oxaliplatin chemotherapy. May persist after treatment and requires dose modification if severe
• Organ toxicity: Specific agents carry organ-specific risks, including cisplatin for kidney and hearing, anthracyclines for heart function and bleomycin for lungs. Baseline organ function assessment and monitoring during treatment are standard.
• Infection risk: Immunosuppression from neutropenia requires patients to recognise and report fever promptly, as neutropenic fever is a medical emergency requiring immediate hospital assessment.

Recovery After Chemotherapy

Recovery from chemotherapy begins during the gaps between treatment cycles and continues after the final session. Most acute side effects like nausea, fatigue and mucositis resolve within two to three weeks of the last cycle. Hair regrowth typically begins within one to two months. Blood counts recover on their own schedule, monitored by regular blood tests.

Some effects take longer. Peripheral neuropathy may take several months to resolve, and in some patients, partial symptoms persist. Cognitive changes (commonly described as 'chemo brain') affecting concentration and memory are recognised and usually improve over six to twelve months. Fatigue can persist beyond the end of treatment, and structured physical activity (as tolerated) is one of the most evidence-supported interventions for post-treatment fatigue.

Nutritional recovery is active, including weight, gut function and appetite normalising over weeks to months, sometimes with nutritional team support. Surveillance for recurrence continues after chemotherapy, with PET CT and clinical review at defined intervals.

Conclusion

Chemotherapy is one of the foundational pillars of cancer treatment and effective across a broader range of cancer types than any other single modality. At Ramkrishna CARE Hospitals, Raipur, it is administered within a full oncology programme – staged with our uMI 550 Digital PET CT, delivered in a purpose-built day care unit and integrated with radiation therapy on the Elekta Versa HD and surgery as required. The goal is effective treatment that is as well-tolerated as possible with the continuity and support that a cancer diagnosis demands.